These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 24252799)

  • 1. Significant clinical response of progressive recurrent ovarian clear cell carcinoma to glypican-3-derived peptide vaccine therapy: two case reports.
    Suzuki S; Shibata K; Kikkawa F; Nakatsura T
    Hum Vaccin Immunother; 2014; 10(2):338-43. PubMed ID: 24252799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: preclinical study using mice.
    Motomura Y; Ikuta Y; Kuronuma T; Komori H; Ito M; Tsuchihara M; Tsunoda Y; Shirakawa H; Baba H; Nishimura Y; Kinoshita T; Nakatsura T
    Int J Oncol; 2008 May; 32(5):985-90. PubMed ID: 18425324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cancer peptide vaccine targeted glypican-3 antigen].
    Nakatsura T
    Nihon Rinsho; 2017 Feb; 75(2):257-262. PubMed ID: 30562861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glypican-3 could be an effective target for immunotherapy combined with chemotherapy against ovarian clear cell carcinoma.
    Suzuki S; Yoshikawa T; Hirosawa T; Shibata K; Kikkawa F; Akatsuka Y; Nakatsura T
    Cancer Sci; 2011 Sep; 102(9):1622-9. PubMed ID: 21668581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The cancer specific antigen, glypican-3 (GPC3)-targeted immunotherapy].
    Sawada Y; Nakatsura T
    Nihon Rinsho; 2012 Dec; 70(12):2136-41. PubMed ID: 23259386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-A2-restricted glypican-3 peptide-specific CTL clones induced by peptide vaccine show high avidity and antigen-specific killing activity against tumor cells.
    Yoshikawa T; Nakatsugawa M; Suzuki S; Shirakawa H; Nobuoka D; Sakemura N; Motomura Y; Tanaka Y; Hayashi S; Nakatsura T
    Cancer Sci; 2011 May; 102(5):918-25. PubMed ID: 21281401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Usefulness of a novel oncofetal antigen, glypican-3, for diagnosis and immunotherapy of hepatocellular carcinoma].
    Nishimura Y; Nakatsura T; Senju S
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):383-91. PubMed ID: 18974622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival.
    Sawada Y; Yoshikawa T; Nobuoka D; Shirakawa H; Kuronuma T; Motomura Y; Mizuno S; Ishii H; Nakachi K; Konishi M; Nakagohri T; Takahashi S; Gotohda N; Takayama T; Yamao K; Uesaka K; Furuse J; Kinoshita T; Nakatsura T
    Clin Cancer Res; 2012 Jul; 18(13):3686-96. PubMed ID: 22577059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide vaccines for hepatocellular carcinoma.
    Nobuoka D; Yoshikawa T; Sawada Y; Fujiwara T; Nakatsura T
    Hum Vaccin Immunother; 2013 Jan; 9(1):210-2. PubMed ID: 23442593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma.
    Suzuki S; Sakata J; Utsumi F; Sekiya R; Kajiyama H; Shibata K; Kikkawa F; Nakatsura T
    Oncoimmunology; 2016; 5(11):e1238542. PubMed ID: 27999758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis.
    Taniguchi M; Mizuno S; Yoshikawa T; Fujinami N; Sugimoto M; Kobayashi S; Takahashi S; Konishi M; Gotohda N; Nakatsura T
    Cancer Sci; 2020 Aug; 111(8):2747-2759. PubMed ID: 32449239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of HLA-A2- or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma.
    Komori H; Nakatsura T; Senju S; Yoshitake Y; Motomura Y; Ikuta Y; Fukuma D; Yokomine K; Harao M; Beppu T; Matsui M; Torigoe T; Sato N; Baba H; Nishimura Y
    Clin Cancer Res; 2006 May; 12(9):2689-97. PubMed ID: 16675560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: an autopsy case.
    Sawada Y; Yoshikawa T; Fujii S; Mitsunaga S; Nobuoka D; Mizuno S; Takahashi M; Yamauchi C; Endo I; Nakatsura T
    Hum Vaccin Immunother; 2013 Jun; 9(6):1228-33. PubMed ID: 23466818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Possibilities of glypican-3-specific immunotherapy for hepatocellular carcinoma].
    Komori H; Nakatsura T; Beppu T; Nishimura Y; Baba H
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1742-4. PubMed ID: 17212093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.
    Iwama T; Uchida T; Sawada Y; Tsuchiya N; Sugai S; Fujinami N; Shimomura M; Yoshikawa T; Zhang R; Uemura Y; Nakatsura T
    Biochem Biophys Res Commun; 2016 Jan; 469(1):138-143. PubMed ID: 26616051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide.
    Tada Y; Yoshikawa T; Shimomura M; Sawada Y; Sakai M; Shirakawa H; Nobuoka D; Nakatsura T
    Int J Oncol; 2013 Oct; 43(4):1019-26. PubMed ID: 23903757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma.
    Ikeda M; Okusaka T; Ohno I; Mitsunaga S; Kondo S; Ueno H; Morizane C; Gemmoto K; Suna H; Ushida Y; Furuse J
    Immunotherapy; 2021 Apr; 13(5):371-385. PubMed ID: 33525928
    [No Abstract]   [Full Text] [Related]  

  • 18. Radiofrequency ablation for hepatocellular carcinoma induces glypican-3 peptide-specific cytotoxic T lymphocytes.
    Nobuoka D; Motomura Y; Shirakawa H; Yoshikawa T; Kuronuma T; Takahashi M; Nakachi K; Ishii H; Furuse J; Gotohda N; Takahashi S; Nakagohri T; Konishi M; Kinoshita T; Komori H; Baba H; Fujiwara T; Nakatsura T
    Int J Oncol; 2012 Jan; 40(1):63-70. PubMed ID: 21922136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials.
    Shi D; Shi Y; Kaseb AO; Qi X; Zhang Y; Chi J; Lu Q; Gao H; Jiang H; Wang H; Yuan D; Ma H; Wang H; Li Z; Zhai B
    Clin Cancer Res; 2020 Aug; 26(15):3979-3989. PubMed ID: 32371538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High glypican-3 expression characterizes a distinct subset of ovarian clear cell carcinomas in Canadian patients: an opportunity for targeted therapy.
    Wiedemeyer K; Köbel M; Koelkebeck H; Xiao Z; Vashisht K
    Hum Pathol; 2020 Apr; 98():56-63. PubMed ID: 32017945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.